-

Axol Bioscience Strengthens Commercial Leadership Team With Key Appointments

Investment in experienced senior and regional management to drive Axol's growth in the global iPSC and related product markets.

CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced the appointment of Ross Wheatcroft as the Global Strategic Accounts Manager. Ross will directly support customers while leading a growing global team of technical account managers. The first of those account managers, Mark Dahlquist, is already in place covering the US's Midwestern and Western regions.

Ross is an accomplished life science sales leader with 18 years of experience in strategic account management, business development, and demonstrated excellence in leading cross-functional teams to develop commercial processes and best practices. The appointment of Ross directly follows Axol's onboarding of a Global Head of Product Management, Kimberly LaPointe, who has equally significant experience and tenure in the life sciences industry. Together, the hires signal Axol's commitment to better serve a dynamic customer base and maximise the potential of its product and service capabilities, particularly in the fast-growing biotech and pharma drug discovery markets.

John Burgess, Chief Business Officer for Axol Bioscience, said: "By bringing on such experienced life science business leaders, we will be better able to provide a level of commercial support that matches our industry-leading products and services. Most importantly, we can ensure a seamless sales journey that expedites the critical work of our customers."

Ross Wheatcroft, Global Strategic Accounts Manager, Axol Bioscience, added:This is a very exciting time for Axol, and I look forward to working with the global team of technical account managers to support the Company’s growth in iPSC stem cell markets.”

For further information about Axol’s products and services, please visit: https://www.axolbio.com

Contacts

For high-resolution images please contact Zyme Communications

Michelle Ricketts
Tel: +44 (0)7789 053 885
E-mail: michelle.ricketts@zymecommunications.com

Axol Bioscience


Release Versions

Contacts

For high-resolution images please contact Zyme Communications

Michelle Ricketts
Tel: +44 (0)7789 053 885
E-mail: michelle.ricketts@zymecommunications.com

Social Media Profiles
More News From Axol Bioscience

Axol Bioscience Acquires Phenocell to Advance Human Disease Models

CAMBRIDGE, England & EDINBURGH, Scotland & GRASSE, France--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders. The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and c...

Axol Bioscience Collaborates With StrataStem to Deliver Stem Cell Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

CAMBRIDGE, England & EDINBURGH, Scotland & ALDERLEY PARK, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogram these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a wide r...

Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery

CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity, offering scientists a robust cardi...
Back to Newsroom